GlassScriptPhysician profile
Louis Y Kim
NPI 1467425405
$8,486.54
in general payments reported to CMS, 2019-2025
35 companies · $599 in 2025
The $599 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,016 · 2020: $1,003 · 2021: $1,147 · 2022: $1,400 · 2023: $1,360 · 2024: $962 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,921.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,726.71 | 2019-2025 | Repatha, Otezla, Prolia |
| Novo Nordisk INC | $870.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $842.14 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $601.91 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Pfizer INC. | $580.65 | 2019-2025 | |
| Astellas Pharma US INC | $517.65 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $410.44 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $338.67 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $332.47 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $313.03 | 2019-2025 | Jardiance, Tradjenta |
| Abbvie INC. | $281.84 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $195.21 | 2019-2024 | Eliquis, Camzyos |
| Allergan, INC. | $177.52 | 2019-2021 | |
| Glaxosmithkline, LLC. | $142.80 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Eisai INC. | $138.37 | 2020-2024 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $114.38 | 2020-2023 | |
| Boston Scientific Corporation | $105.52 | 2022 | |
| Abbott Laboratories | $105.42 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Amarin Pharma, INC. | $82.52 | 2019-2022 | |
| Edwards Lifesciences Corporation | $82.50 | 2022 | |
| Merck Sharp & Dohme LLC | $72.60 | 2019-2020 | |
| Radius Health, INC. | $71.47 | 2019-2024 | Tymlos |
| Corcept Therapeutics | $46.69 | 2022-2023 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.81 | 2023 | |
| Exact Sciences Corporation | $42.36 | 2023-2025 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $41.82 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.90 | 2019-2023 | Trintellix |
| Axsome Therapeutics, INC. | $32.22 | 2025 | Auvelity |
| Almatica Pharma LLC | $28.06 | 2022 | |
| Welch Allyn | $24.38 | 2021 | |
| Circassia INC. | $23.71 | 2019-2020 | |
| Viiv Healthcare Company | $18.29 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $18.15 | 2023 | Rexulti |
| Paratek Pharmaceuticals, INC. | $14.83 | 2021 | |
| Sumitomo Pharma America, INC. | $13.17 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.